Positive association between severity of COVID-19 infection and liver damage: a systematic review and meta-analysis COVID-19 Infection and Liver Injury
Gastroenterology and Hepatology from Bed to Bench,
,
20 September 2020
,
Page 292-304
https://doi.org/10.22037/ghfbb.v13i4.2129
Abstract
Aim: The current study aimed to report a pooled analysis of the association of the circulating levels of liver enzymes and total bilirubin with severe and non-severe COVID-19.
Background: The ongoing coronavirus outbreak is an important threat to health worldwide. Epidemiological data representing greater risk of liver failure in patients infected with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
Methods: Electronic databases were comprehensively searched using Medline, ISI Web of Science, EMBASE, and the Cochrane Library up to July 2020. Outcomes from each relevant study were pooled using a random-effects model. Heterogeneity was analyzed by Q test and I2 statistics. Sensitivity analysis was also evaluated.
Results: A total of 24 studies were included (4,246 patients) in this study. We found a significant association of COVID-19 severity with increased levels of ALT [SMD: 1.40 U/L; 95% CI (0.93, 1.88); P < 0.05, I2 = 96.5%, PHeterogenity = 0.000 ], AST [SMD: 2.11 U/L; 95% CI (1.40, 2.83); P < 0.05, I2 = 97.9%, PHeterogenity = 0.000], LDH [SMD: 3.88 U/L; 95% CI (2.70, 5); P < 0.05, I2 = 98.7%, PHeterogenity = 0.000] and TBil [SMD: 1.08 mmol/L; 95% CI (0.44, 1.72); P = 0.001, I2 = 97.7, PHeterogenity = 0.000], whereas, ALP values [SMD: 0.31; 95% CI (-1.57, 2.20); P = 0.74] was not significant between severe and non-severe COVID-19 patients. Moreover, elevated liver enzymes were found more in males [OR: 1.52, (95% CI 1.26, 1.83), P < 0.05] with severe COVID-19 infection than in females.
Conclusion: The alterations of liver function indexes caused by SARS-CoV-2 infection suggested a potential prognosis biomarker for screening of severe patients at early stages of the disease.
Keywords: COVID-19, Coronavirus, Liver damage, Liver enzymes, Meta-analysis.
(Please cite as: Shokri Afra H, Amiri-Dashatan N, Ghorbani F, Maleki I, Rezaei-Tavirani M. Positive association between severity of COVID-19 infection and liver damage: a systematic review and meta-analysi. Gastroenterol Hepatol Bed Bench 2020;13(4):292-304).
- COVID-19, Coronavirus, Liver damage, Liver enzymes, Meta-analysis.
References
Organization WH. Coronavirus disease 2019 (COVID-19): situation report, 72. 2020.
Sohrabi C, Alsafi Z, O’Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). International Journal of Surgery. 2020.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet 2020;395:497-506.
Shi Q, Zhao K, Yu J, Jiang F, Feng J, Zhao K, et al. Clinical characteristics of 101 COVID-19 nonsurvivors in Wuhan, China: a retrospective study. medRxiv 2020. https://doi.org/10.1101/2020.03.04.20031039.
Lei Y, Ian Y, Iu J, Huang X,Silang B, Zeng F. Clinical features of imported cases of coronavirus disease 2019 in Tibetan patients in the Plateau area. medRxiv 2020. http://dx.doi.org/10.1101/2020.03.09.20033126.
Wang X, Fang J, Zhu Y, Chen L, Ding F, Zhou R, et al. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital. Clin Microbiol Infect 2020;26:1063:68.
Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet 2020;395:514-23.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama 2020;323:1061-9.
Omrani-Nava V, Maleki I, Ahmadi A, Moosazadeh M, Hedayatizadeh-Omran A, Roozbeh F, et al. Evaluation of Hepatic Enzymes Changes and Association with Prognosis in COVID-19 Patients. Hepat Mon 2020;20:e103179.
Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020;5:428-30.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-2.
Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020;40:998-1004.
Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020;8:475-81.
Knottnerus A, Tugwell P. STROBE--a checklist to Strengthen the Reporting of Observational Studies in Epidemiology. J Clin Epidemiol 2008;61.
Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573-7.
Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analysis: advantages and limitations of the Newcastle Ottawa Scale. World J Meta-Anal 2017;5:1-48.
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Mehodol 2005;5:1-10.
Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-analysis, version 2. Englewood, NJ:Biostat 2005;104.
Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 2020;115:766-73.
Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;69:1002-09.
Liu C, Jiang Z, Shao C, Zhang H, Yue H, Chen Z, et al. Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study. Chin J Hepatol 2020;28:148-52.
Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID‐19 in a Designated Infectious Diseases Hospital Outside Hubei Province, China. Allergy 2020;00:1-11.
Cao W, Shi L, Chen L, Xu X, Wu Z. Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei. medRxiv 2020. http://dx.doi.org/10.21203/rs.3.rs-15925/v1.
Qian Z, Mei X, Zhang Y, Zou Y, Zhang Z, Zhu H, et al. Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area. Chin J Hepatol 2020;28:E005-E.
Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, et al. Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series. QJM 2020;113:474-81.
Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of Non‐ICU hospitalized patients with coronavirus disease 2019 and liver injury： A Retrospective study. Liver Int 2020;40:1321-26.
Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020;368:m1295.
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H. Clinical and immunologic features in severe and moderate forms of Coronavirus Disease. J Clin Invest 2019;137244.
Deng Y, Liu W, Liu K, Fang YY, Shang J, Wang K, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study. Chin Med J 2020;133:1261-67.
Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J 2020;133:1032-38.
Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis 2020;ciaa270.
Qu R, Ling Y, Zhang Yh, Wei Ly, Chen X, Li X, et al. Platelet‐to‐lymphocyte ratio is associated with prognosis in patients with Corona Virus Disease‐19. J Med Virol 2020;10.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846-48.
Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical Features and Treatment of COVID‐19 Patients in Northeast Chongqing. J Med Virol 2020:92:797-806.
Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis 2020;71:769-77.
Zhou B, She J, Wang Y, Ma X. The clinical characteristics of myocardial injury in severe and very severe patients with 2019 novel coronavirus disease. J Infect 2020;81:147-78.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.
Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020. doi:10.1001/jamainternmed.2020.0994.
Zhang X, Cai H, Hu J, Lian J, Gu J, Zhang S, et al. Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. Int J Infect Dis 2020;395.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020;395:507-13.
Huang Y, Zhou H, Yang R, Xu Y, Feng X, Gong P. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. medRxiv 2020. https://doi.org/10.1101/2020.02.27.20029009.
Nasiri MJ, Haddadi S, Tahvildari A, Farsi Y, Arbabi M, Hasanzadeh S, et al. COVID-19 clinical characteristics, and sex-specific risk of mortality: Systematic Review and Meta-analysis. Front Med 2020;7:459.
Luedde T, Kaplowitz N, Schwabe RF. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 2014;147:765-83.
Humar A, McGilvray I, Phillips MJ, Levy GA. Severe acute respiratory syndrome and the liver. Hepatology 2004;39:291.
Saad M, Omrani AS, Baig K, Bahloul A, Elzein F, Matin MA, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 2014;29:301-6.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-80.
Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clinical infectious diseases 2020; doi: 10.1093/cid/ciaa449.
Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. BioRxiv 2020. https://doi.org/10.1101/2020.02.03.931766.
Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;25:193-7.
Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 2020;34:327-31.
Yao X, Li T, He Z, Ping Y, Liu H, Yu S, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Chin J Pathol 2020;49:E009-E.
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020;71:762-68.
Li J, Fan JG. Characteristics and mechanism of liver injury in 2019 coronavirus disease. J Clin Transl Hepatol 2020;8:13-17.
Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical features of COVID-19-related liver damage. Clin Gastroenterol Hepatol 2020;18:1561–66.
Chang HL, Chen KT, Lai SK, Kuo HW, Su IJ, Lin RS, et al. Hematological and biochemical factors predicting SARS fatality in Taiwan. J Formos Med Assoc 2006;105:439-50.
Al Ghamdi M, Alghamdi KM, Ghandoora Y, Alzahrani A, Salah F, Alsulami A, et al. Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect Dis 2016;16:174.
Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020;14:185-92.
- Abstract Viewed: 0 times
- PDF Downloaded: 0 times
